Evaluation of tumor microvascular response to brivanib by dynamic contrast-enhanced 7-T MRI in an orthotopic xenograft model of hepatocellular carcinoma

American Journal of Roentgenology

Volumn 202, Issue 6, 2014, Pages

  Song, Kyoung Doo ^a   Choi, Dongil ^a   Lee, Jung Hee ^a   Im, Geun Ho ^a   Yang, Jehoon ^b   Kim, Jae Hun ^a   Lee, Won Jae ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Brivanib; Dynamic contrast enhanced MRI; Microvessel density; Perfusion

Indexed keywords

BRIVANIB; CD31 ANTIGEN; ALANINE; ANGIOGENESIS INHIBITOR; CONTRAST MEDIUM; DRUG DERIVATIVE; TRIAZINE DERIVATIVE; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CAPILLARY DENSITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG MONITORING; DRUG POTENCY; DRUG RESPONSE; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; EXTRACELLULAR SPACE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; MICROVASCULATURE; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; DRUG ANTAGONISM; DRUG EFFECT; LIVER TUMOR; METHODOLOGY; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PATHOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VASCULARIZATION;

ADMINISTRATION, ORAL; ALANINE; ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROVESSELS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TRIAZINES; TUMOR BURDEN;

EID: 84904131641     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.13.11042     Document Type: Article

References (27)

1. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2:795-803 (Pubitemid 37328914)
2. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-676 (Pubitemid 36749215)
3. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407:242-248
4. Ellis LM, Fidler IJ. Angiogenesis and metastasis. Eur J Cancer 1996; 32A:2451-2460
5. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134 (Pubitemid 46089673)
6. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-2676
7. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124 (Pubitemid 46089672)
8. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-2550 (Pubitemid 44917502)
9. 1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f] [1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem 2006; 49:2143-2146
10. Muruganandham M, Lupu M, Dyke JP, et al. Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T. Mol Cancer Ther 2006; 5:1950-1957 (Pubitemid 44336566)
11. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003; 21:3955-3964 (Pubitemid 46606209)
12. Pham CD, Roberts TP, van Bruggen N, et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 1998; 16:225-230 (Pubitemid 28211008)
13. Brasch R, Pham C, Shames D, et al. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imaging 1997; 7:68-74 (Pubitemid 28365640)
14. Huynh H, Ngo VC, Fargnoli J, et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008; 14:6146-6153
15. Pedersen M, Morkenborg J, Jensen FT, Stodkilde-Jorgensen H, Djurhuus JC, Frokiaer J. In vivo measurements of relaxivities in the rat kidney cortex. J Magn Reson Imaging 2000; 12:289-296 (Pubitemid 30612873)
16. Fram EK, Herfkens RJ, Johnson GA, et al. Rapid calculation of T1 using variable flip angle gradient refocused imaging. Magn Reson Imaging 1987; 5:201-208 (Pubitemid 17133355)
17. 1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10:223-232
18. Kim JH, Im GH, Yang J, Choi D, Lee WJ, Lee JH. Quantitative dynamic contrast-enhanced MRI for mouse models using automatic detection of the arterial input function. NMR Biomed 2012; 25:674-684
19. Shinriki S, Jono H, Ota K, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res 2009; 15:5426-5434
20. Bhide RS, Lombardo LJ, Hunt JT, et al. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol Cancer Ther 2010; 9:369-378
21. Wilmes LJ, Pallavicini MG, Fleming LM, et al. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 2007; 25:319-327 (Pubitemid 46413652)
22. Flaherty KT, Rosen MA, Heitjan DF, et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 2008; 7:496-501 (Pubitemid 351847022)
23. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24:769-777 (Pubitemid 46622044)
24. Akisik MF, Sandrasegaran K, Bu G, Lin C, Hutchins GD, Chiorean EG. Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy. Radiology 2010; 256:441-449
25. Kim H, Folks KD, Guo L, et al. Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging. Mol Imaging 2011; 10:153-167
26. Merz M, Komljenovic D, Semmler W, Bauerle T. Quantitative contrast-enhanced ultrasound for imaging antiangiogenic treatment response in experimental osteolytic breast cancer bone metastases. Invest Radiol 2012; 47:422-429
27. Hoyt K, Sorace A, Saini R. Quantitative mapping of tumor vascularity using volumetric contrast-enhanced ultrasound. Invest Radiol 2012; 47:167-174